Tony Pantalleresco Radio Show notes – November 1st 2014

Tony Pantallaresco

Welcome to Tony Pantalleresco Radio Show notes – November 1st 2014

Topics in this show include:

Tea, citrus products could lower ovarian cancer risk, new research finds

SaskPower CEO resigns after smart meter report


Silver nanoparticle applications and human health

Purslane weed (Portulaca oleracea): a prospective plant source of nutrition,

omega-3 fatty acid, and antioxidant attributes.

PSA test should be abandoned as screen for prostate cancer, task force says
Could copper prevent spread of Ebola

Continue reading

Omega-3 structure may affect bioavailability: Study

Omega-3 structure may affect bioavailability: Study

By Nathan Gray, 14-Jan-2011

Related topics: Research

The type of omega-3 we take may have a distinct affect on how much is actually absorbed, according to new research.

The study, published in the European Journal of Lipid Science and Technology, suggests that omega-3concentrates – such as triacylglycerides – have much better bioavailability than purified fish oil.

The team of Spanish researchers said that the study contributes to knowledge on the intestinal lipolysis of omega-3 sources, which can be found in many commercial forms, from purified fish oil to concentrates of free fatty acids and ethyl esters.

They said that despite differences regarding their intestinal metabolism, there is lack of information about the specific composition of the absorbable fraction from omega-3-TAG or omega-3-EE concentrates.

“This comparative study showed that the in vitro bioaccesibility of omega-3-polyunsaturated fatty acid (PUFA) seems to be better as omega-3-TAG concentrates than purified fish oils,” said the researchers, led by Dr. Diana Martin from the Universidad Autónoma de Madrid, Spain.

Fish oil

Consumption of fatty acids from the omega-3 family – particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) – have been advised due to their beneficial role as anti-thrombotic, anti-inflamatory, and hypolipidemic fatty acids.

The authors noted, however, that in many populations consumption of fish is quite low and does not achieve levels adequate for reaching the minimal intake level of EPA and DHA. They added that because of this, an easy way of increasing omega-3-polyunsaturated fatty acids (PUFA) intake is by the fish oils supplements oils.

They said that recent studies have produced contradictory evidence for the in vitro metabolism of fish oils and omega-3-concentrates,

The new study compared the in vitro bioaccesibility of omega-3-oils from different sources. The researchers tested salmon oil, tuna oil, enriched-omega-3 oil as triacylglycerols (omega-3-TAG), and enriched-omega-3 oil as ethyl ester (omega-3-EE).

Study details

Dr Martin and colleagues reported the rate of hydrolysis of omega-3-TAG concentrates was continuous throughout the time of reaction, whereas the digestion of salmon oil and tuna oil was initially faster but stopped after 10 min.

They added that poor hydrolysis took place for the enriched-omega-3 oil as omega-3-EE.

The breakdown of omega-3-TAG oil, salmon oil, and tuna oil mainly consisted of free fatty acids (FFAs) and monoacylglycerides, whereas the breakdown from digested omega-3-EE oil consisted of free fatty acids and undigested ethyl esters.

“This comparative study showed that the in vitro intestinal digestion of omega-3 (EPA and DHA) sources as fish oil, triacylglycerides, or ethyl ester concentrates was different,” said Martin and colleagues.

“The highest degree of hydrolysis and inclusion of lipid products … was found for the omega-3-TAG oil, but compared to fish oils long times of digestion were required,” they added.

Source: European Journal of Lipid Science and Technology
Volume 112, Issue 12, pages 1315–1322, doi: 10.1002/ejlt.201000329
“Intestinal digestion of fish oils and ω-3 concentrates under in vitro conditions”
Authors: D. Martin, J.A. Nieto-Fuentes, F.J. Señoráns, G. Reglero, C. Soler-Rivas

Sales are niche, but “omega-3 craze” is not over, says industry

Sales are niche, but “omega-3 craze” is not over, says industry

Post a commentBy Shane Starling, 21-Dec-2010

Related topics: Health claims, Omega-3, Industry, Nutritional lipids and oils, Cardiovascular health, Cognitive and mental function

High-profile omega-3 product withdrawals or underperforming products do not signal a crisis in the category, rather an acknowledgement of its nascent status, industry figures have said.


Danino spells ‘withdrawn’ in Canada

Responding to a recent article in Kids Nutrition Report (KNR) that highlighted market removal of a Danone DHA-fortified yogurt in Canada called Danino and underwhelming sales of a Sara Lee DHA bread in the US, Ocean Nutrition Canada chairman Robert Orr said the state of play reflected an industry that was still figuring out the best way to incorporate omega-3s into foods and market them.

Orr said the global deficiency in omega-3s was only slowly being addressed, the broader functional foods market still developing, and therefore sectors like his were taking the “long view”.

“Yes there have been failures – but the omega-3 success rate for new products is still significantly better than average of new products,” he said, noting sales were modest but above other food industry sectors.

“Yes they will remain predominantly niche and lifestyle oriented for some years yet as the food industry figures out how to market health and products that cost more because their ingredients cost more.”


“The truth is that EPA and DHA are important to human health and well being. Omega-3s are among the largest dietary deficiencies in the western diet. The need and demand to improve health is not going away.”




The KNR story said another product, a Unilever omega-3 dairy drink called Amaze marketed with brain health claims, had been pulled from the market in Turkey after four years and was no longer showing up in Unilever’s Indian communications.

“Omega-3 has become a major success in some areas: around the world the omega-3 dietary supplement business is thriving, with supplement sales up 10% in the US in 2010, to over $1 billion (€750 million), making omega-3 the biggest dietary supplement category,” the article states.


“Omega-3 has also become a standard ingredient in infant formula. But in food and beverage the omega-3 craze is over – until the omega-3 industry rethinks its strategy. Every year producers of omega-3 oils – from marine and from algal sources – hope for their big-break through. And every year produces another disappointment; 2010 was no exception, and until there’s a major re-think among ingredient suppliers about their technology and strategy, 2011 will be no better, and nor will any following year.”

The article goes on to highlight how formulation improvements are necessary to enable higher-dose foods and drinks to compete with dietary supplements and other heart health offerings like pomegranate and fiber.


KNR said the establishment of recommended dietary intakes (RDIs) which the omega-3 industry had lobbied for and been rewarded with in the European Union recently, would not be as valuable as the industry expected.

“Japan has an RDA for omega-3 fatty acids – it is recommended that 2,600mg of DHA be consumed daily – but even so it’s had limited effect on the omega-3 market. Japanese people prefer to get their omega-3 from fish or from supplements – and Westerners are showing every sign of going the same way.”


Adam Ismail, the executive director of the Global Organization for EPA and DHA Omega-3s (GOED) said RDIs were important for reasons that were not directly related to their on-package advice.

“An RDI does provide a point of differentiation, in that those countries where omega-3s have RDIs make omega-3s the only ingredient for heart health that has the recognition of an RDI (with the exception of vitamin E),” he said.

“Also, health claims and fortification levels tend to stem from RDIs. In Europe for example, the new daily recommended value (DRV) for omega-3s is actually based on its heart health benefits, and the dosage levels required for using heart health claims will in turn based on this DRV. So in countries with meaningful RDIs, consumers get meaningful dosages in their products.”

GOED will be discussing the issue of RDIs at a conference it is hosting in Salt Lake City on January 14-15, 2011.

DSM buys Martek’s “algae platform” for $1bn

DSM buys Martek’s “algae platform” for $1bn

1 commentBy Shane Starling, 21-Dec-2010

Related topics: Omega-3, Industry, Nutritional lipids and oils

Royal DSM will drive Martek’s predominantly US-based, omega-3 DHA infant nutrition business to new shores, and fast-track its food and beverage ambitions, after having its billion-dollar bid accepted by the Maryland company’s Board.


Martek becomes DSM’s biggest acquisition since its 2002 purchase of Roche Vitamins

The cash deal for $1.087bn (€829m), if it is accepted by Martek’s shareholders next month, represents the largest investment by DSM’s nutrition arm since it paid €2.5bn for the vitamins business of Roche in 2002, board member Stephan Tanda told NutraIngredients this morning.He said that while DSM possesses an omega-3 ingredient called Ropufa, it is fish-sourced and has not been targeted at the infant nutrition sector, instead favouring traditional foods and supplements. Nor does it have the, “strong vegetarian, algae platform that also offers industrial biochemical and pharma potential”. 
    Third party credit rating agencies said DSM had an investment fund of between €2.5-€3bn before the Martek offer, and Tanda said the company continued to eye acquisition targets. Tanda said DSM’s global reach would enable it to develop Martek’s DHA (docosahexaenoic acid) infant nutrition business in Asia, Europe and other markets, with dietary supplements and feed markets also a priority.The move comes at the end of a year in which DSM launched fish-sourced versions of its DHA ingredient aimed at the infant nutrition market, and Martek signalled its move to extract EPA (eicosapentaenoic acid) from its algae vats.It was not made clear what would happen to these initiatives, in the light of the acquisition.Tanda said Martek’s ‘life’sDHA’ brand would be retained, if not the Martek name itself.Market analysts told NutraIngredients that the Martek acquisition and others in the chemicals area reflected a strategic decision by DSM to stave off persistent rumours of itself being an acquisition target
Channels and premiums
DSM had no intention of selling Martek’s recently acquired consumer supplements brand Amerifit. “This is a nice fit,” he said. “It’s a good channel for ingredients for Martek and DSM.”The $31.50 offer amounts to a 35 per cent premium for NASDAQ listed Martek shareholders over yesterday’s closing share price of $23.36 – a typical premium for such buy-outs. It is a 39 per cent premium over the average price of the stock for the past 90 days.Martek, which has annual revenue of $450m, and DSM have a working relationship as they have worked together on omega-6 ARA (arachidonic acid) for almost 20 years. “We are pleased that this transaction appropriately recognizes the value of Martek’s nutritional ingredients, technology platform, market position and skilled workforce, while providing significant value to our stockholders,” said Martek chief executive officer, Steve Dubin. “We have worked collaboratively with DSM for many years, and we are confident that they share our vision for Martek’s future.” Martek was not available for further comment at the time of publication.In the same statement, Feike Sijbesma, chief executive officer/chairman of the DSM Managing Board said: “This acquisition is an attractive and logical next step for DSM. Martek’s leading position in healthy, natural ingredients and algal technology will add a new growth platform to our Nutrition business. DSM is a unique partner for Martek and, with our strong track record of growing businesses in competitive environments, we believe we can help to lift Martek to the next level.”